Compare SRCE & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRCE | OGN |
|---|---|---|
| Founded | 1863 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1995 | 2020 |
| Metric | SRCE | OGN |
|---|---|---|
| Price | $73.15 | $13.38 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 5 |
| Target Price | ★ $74.50 | $11.40 |
| AVG Volume (30 Days) | 85.0K | ★ 5.7M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.37% | 0.60% |
| EPS Growth | ★ 19.59 | N/A |
| EPS | ★ 1.63 | 0.55 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | $10.29 | $0.45 |
| Revenue Next Year | $3.16 | $1.67 |
| P/E Ratio | $45.18 | ★ $24.34 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $56.89 | $5.69 |
| 52 Week High | $76.44 | $13.48 |
| Indicator | SRCE | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.22 | 75.13 |
| Support Level | $71.36 | $10.05 |
| Resistance Level | $75.42 | $13.46 |
| Average True Range (ATR) | 1.58 | 0.06 |
| MACD | 0.02 | -0.22 |
| Stochastic Oscillator | 42.70 | 47.50 |
1st Source Corp provides specialized financing services for construction equipment, aircraft, and vehicle types through its Specialty Finance activities. The company offers commercial, small business, agricultural, and real estate loans, along with commercial leasing, treasury management, and payment services, including Fedwires, ACH, and merchant services. It also provides Renewable Energy Financing for commercial solar projects, a full range of consumer banking products, Trust and Wealth Advisory Services, and insurance products. The company operates in the commercial banking segment, which provides commercial and consumer banking services, trust and wealth advisory services, and insurance to individual and business clients across its markets.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.